Apeximmune seeks to be a preeminent leader in the discovery and development of novel biologics that modulate the immune system for the treatment of a broad spectrum of indications including cancer, autoimmune disease, and transplantation.
We focus on the science underlying what we believe to be the most powerful biological mechanisms driving disease pathophysiology. Our technology platform combines bioinformatics with biological assays to enable identification of novel immune modulating targets. With a team encompassing expertise in immunology, cellular and molecular tumor biology, protein characterization and optimization, and pharmacokinetics, we are developing biologics/antibodies to treat disease through these mechanisms.
Li-Fen Lee, Ph.D.
Founder and CEO
Li-Fen Lee is deeply versed in the fields of immunology and immuno-oncology (IO) and has successfully carried several drug candidates from target validation all the way to clinical trials. She previously led a drug discovery group at Rinat-Pfizer and made significant contributions to the development of therapeutic antibodies against IL-7R and various costimulatory molecules aimed at treating autoimmune diseases and cancer. Her work, which included several IND filings and patents as well as numerous high impact publications, was recognized with the prestigious Pfizer Achievement Award. Later, Li-Fen joined NGM Biopharmaceuticals as an Associate Director where she established the core IO infrastructure and helped build the IO pipeline. Following that, she served as the Director of IO at Pharmacyclics, an Abbvie company.
Prior to joining industry, Li-Fen held a 5-year NIH career development grant and a faculty position at the Stanford University School of Medicine, where she studied autoimmune disease and hematopoietic stem cell transplantation. She received her Ph.D. in Biology at the University of North Carolina, Chapel Hill where she was a recipient of the Lineberger Graduate Fellow Award.
Ching-Leou Teng, Ph.D.
Ching-Leou currently serves as Chairperson of PharmaEssentia Corporation where she manages global strategy and development. She helped lead the company to its initial public offering on the Taipei Exchange in Taiwan, and has moved the leading drug candidate Ropeginterferon alfa-2b from preclinical to Phase III trials in both the European Union and the United States. Ching-Leou previously served as a Reviewer of the Pharmacokinetics Evaluation Branch, Division of Biopharmaceutics, at the U.S. Food and Drug Administration (FDA). She was also formerly Assistant Director of Drug Delivery Research and Pharmaceutical Development at Ionis Pharmaceuticals, where she led new drug development, manufacturing and processing validation, CMC, and preclinical studies for both IND and NDA approvals.
Ching-Leou received a Ph.D. in Pharmaceutics at the University of Michigan.
Hsieng Lu, Ph.D.
Hsieng Lu is an expert in analytical protein characterization with more than 30 years of experience in the development of large molecular pharmaceuticals. Over his long career at Amgen, Inc., he was instrumental to the discovery and identification of several important protein therapeutic candidates including novel cytokines/growth factors, Fc-fusion proteins, as well as antibodies and derivatives including antibody-drug conjugates and bispecifics. He contributed to numerous IND filings for protein therapeutics and BLA filings for marketed biologics. As a Director of Research, he led a core group performing protein structural analysis, characterization, and CMC analytical support. His group harnessed emerging analytical technologies in physicochemical analytics, mass spectrometry, and molecular interaction platforms using state of the art instrumentation. Hsieng also served on the Amgen Biologics senior team, collaborating cross-functionally with project teams to facilitate IP support, lead candidate selection, technology devlopment, and in-licensing opportunities.
Hsieng received a Ph.D. in Biochemistry from the Department of Chemistry at the University of North Texas. He has authored more than 100 peer-reviewed publications and book chapters and is a co-inventor on numerous patents for protein biologics and antibodies. He currently serves as a consultant to the biotechnology industry.